Lab
Lab at Seascape
Lab at Seascape was paid $472K by Medicaid between Jan 2019 and Oct 2024, across 28 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 64% of everything it billed.
33Billing provider infoLAB AT SEASCAPE
MILFORD, DE 19963
MILFORD, DE 19963
33aNPI1770053548assigned 12/04/2018
33bProvider typeClinical Medical Laboratory
28Total paid$472K
24GClaims86,363
24DCodes billed28
24AFirst – last monthJan 2019 – Oct 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Delaware
Rank by total paid#4 of 11
Median peer was paid$134K
This provider vs. median3.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 16,265 | $134.94 | |
| 2020 | 10,264 | $28K | |
| 2021 | 26,056 | $208K | |
| 2022 | 13,762 | $161K | |
| 2023 | 11,020 | $41K | |
| 2024incomplete | 8,996 | $34K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 64% | 14,351 | 5,985 | $304K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 9.6% | 7,257 | 2,756 | $45K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 9.2% | 6,286 | 2,971 | $43K |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 5.9% | 21,188 | 9,168 | $28K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.0% | 3,831 | 1,878 | $14K |
| 36415 | Collection of venous blood by venipuncture | 1.6% | 13,285 | 6,581 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 4,011 | 2,568 | $6K |
| 80053 | Comprehensive metabolic panel | 1.1% | 2,865 | 2,062 | $5K |
| 85027 | <1% | 3,755 | 2,566 | $5K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 406 | 194 | $4K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,631 | 1,749 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 149 | 71 | $2K |
16 more codes
| 80061 | Lipid panel | <1% | 1,096 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,204 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 635 | $510.17 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 309 | $248.05 |
| 87088 | <1% | 467 | $241.13 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 66 | $203.66 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 24 | $162.86 |
| P9615 | Catheterization for collection of specimen(s) (multiple patients) | <1% | 338 | $160.00 |
| 87186 | <1% | 56 | $154.51 | |
| 87077 | <1% | 57 | $144.31 | |
| 83735 | <1% | 165 | $102.78 | |
| 81003 | <1% | 427 | $80.91 | |
| 81001 | <1% | 131 | $76.78 | |
| 80076 | <1% | 15 | $16.02 | |
| 85610 | <1% | 1,313 | $5.25 | |
| 80164 | 0% | 45 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILSON, RICHARD (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| MD Partners, PLLC | Benton, KY | $766K |
| Advanced Eyecare PC | Raytown, MO | $68K |
| Wilson Medical Staffing PLLC | Paducah, KY | $48K |
| Advanced Eyecare PC | Blue Springs, MO | $7K |
| Richard R. Wilson, D.O. | Estero, FL | $5K |
| Advanced Eyecare, PC | Raymore, MO | $65.70 |
| Richard a Wilson JR MD PC | Washington, DC | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.